2 weeks Ago By Defense World Staff
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Research analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst M.
Foroohar forecasts that the company will earn ($3.82) per share for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.
84) per share. 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.
90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10).
Several other research firms have also issued reports on FDMT. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.
00 in a research report on Monday, January 13th. Royal Bank of Canada lowered their price objective on 4D Molecular Therapeutics from $39.00 to $35.
00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd.
Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Tuesday, April 8th. Finally, Bank of America dropped their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.
00 and set a “buy” rating on the stock in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.
com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $26.71.Check Out Our Latest Research Report on 4D Molecular Therapeutics4D Molecular Therapeutics Price PerformanceFDMT opened at $3.
06 on Thursday. The firm has a market capitalization of $141.68 million, a P/E ratio of -1.
07 and a beta of 2.89. 4D Molecular Therapeutics has a one year low of $2.
24 and a one year high of $28.93. The company has a fifty day moving average price of $3.
80 and a 200-day moving average price of $5.94. Institutional Trading of 4D Molecular TherapeuticsLarge investors have recently added to or reduced their stakes in the company.
Vanguard Group Inc. increased its holdings in shares of 4D Molecular Therapeutics by 3.4% in the 4th quarter.
Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock worth $15,933,000 after buying an additional 92,791 shares during the last quarter. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 1.
8% during the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock valued at $22,879,000 after purchasing an additional 37,232 shares in the last quarter. Millennium Management LLC lifted its holdings in 4D Molecular Therapeutics by 1,607.
1% during the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock worth $7,913,000 after buying an additional 1,337,497 shares during the period. JPMorgan Chase & Co.
boosted its holdings in shares of 4D Molecular Therapeutics by 159.5% in the 4th quarter. JPMorgan Chase & Co.
now owns 820,069 shares of the company’s stock valued at $4,568,000 after buying an additional 504,086 shares in the last quarter. Finally, Norges Bank purchased a new position in 4D Molecular Therapeutics in the fourth quarter worth $2,790,000. Institutional investors own 99.
27% of the company’s stock. 4D Molecular Therapeutics Company Profile (Get Free Report)4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Further ReadingFive stocks we like better than 4D Molecular Therapeutics3 Healthcare Dividend Stocks to BuyTariff Exemptions Set the Stage for a Taiwan Semiconductor RallyCompound Interest and Why It Matters When InvestingMitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. DollarInsider Trading – What You Need to KnowBroadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk.
